首頁
C4 Therapeutics

7月 2026C4 Therapeutics的市場佔有率分析

It has been brought to our attention that there have been instances of fraudulent job offers, claiming to be from C4 Therapeutics. These individuals have been offering fraudulent employment opportunities to applicants and often asking candidates to provide sensitive personal and financial information, including asking for payments to purchase necessary equipment or software for jobs […]

科學與教育 > 生物學

域名c4therapeutics.com

成立年份2010

僱員51 - 200

年度營收$25M - $50M

C4 Therapeutics

C4 Therapeutics（包含公司地區）

c4therapeutics.com

查看更多網站流量與參與度資訊

C4 Therapeutics截至 7月 2026 的總收入為 25M - 50M

C4 Therapeutics 熱門網域產生的總收入

C4 Therapeutics 熱門網域 3 年內的總收入

C4 Therapeutics 熱門網域的總收入

c4therapeutics.com25M - 50M

透過銷售情報查看更多內容

C4 Therapeutics的熱門網域總造訪量

了解C4 Therapeutics市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

c4therapeutics.com5.1K

透過銷售情報查看更多內容

C4 Therapeutics的熱門網域平均造訪時長

分析C4 Therapeutics參與度指標。

過去 3 個月平均造訪時長

子公司細目

c4therapeutics.com00:00:46

透過銷售情報查看更多內容

C4 Therapeutics的熱門網域平均頁面瀏覽量

了解C4 Therapeutics如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

c4therapeutics.com1.73

透過銷售情報查看更多內容

C4 Therapeutics按網域劃分的熱門競爭對手

7月 2026的熱門類似網站，依相似度排名

rigel.com公司名Rigel Pharmaceuticals僱員51 - 200總部美國, 加利福尼亞, South San Francisco年度營收$200M - $500M訪問總量13.2K健康 > 生物技術和製藥

使用的熱門技術C4 Therapeutics

这些是C4 Therapeutics顶级域名使用的行业网站技术

付款與貨幣 (10)

Cart Functionality

社群 (9)

Google+ Platform

小工具 (8)

Twemoji

付費廣告 (7)

DoubleClick

更多技術

11

檢視所有

新聞與訊號來自C4 Therapeutics

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞C4 Therapeutics, Inc. had revenue of $6.64M on Jul 1st '26.* C4 Therapeutics reported a quarterly loss of $0.18 per share, beating the consensus loss estimate of $0.23, while revenue of $6.64 million exceeded expectations of $4.00 million.

新聞C4 Therapeutics, Inc. identified as competitor of Bristol-Myers Squibb Co on May 1st '26.C4 Therapeutics' stock price appreciated ahead of competitor Bristol Myers Squibb's data presentation at the American Society of Clinical Oncology (ASCO) conference for its drug mezigdomide, a drug with a comparable mechanism of action to C4's cemsidomide for the treatment of multiple myeloma.

新聞C4 Therapeutics, Inc. partnered with Roche on Apr 1st '26.C4 Therapeutics (Nasdaq: CCCC) received a USD 20 million upfront when it expanded its degrader-antibody conjugate collaboration with Roche in April 2026, in a deal worth over USD 1 billion in total commitments, with Roche paying a premium for bexobrutideg's later clinical stage.